Related references
Note: Only part of the references are listed.CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Fusobacterium nucleatum - symbiont, opportunist and oncobacterium
Caitlin A. Brennan et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Jorge Blando et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
Sarah Whelan et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity
Benjamin Murter et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TIGIT signaling restores suppressor function of Th1 Tregs
Liliana E. Lucca et al.
JCI INSIGHT (2019)
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
Catherine A. Sabatos-Peyton et al.
ONCOIMMUNOLOGY (2018)
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a
Ingrid Julienne Georgette Burvenich et al.
THERANOSTICS (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Cancer immunologists scoop medicine Nobel prize
Heidi Ledford et al.
NATURE (2018)
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Journal for ImmunoTherapy of Cancer (2018)
CD226 opposes TIGIT to disrupt Tregs in melanoma
Julien Fourcade et al.
JCI INSIGHT (2018)
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
Liqin Liu et al.
CLINICAL CANCER RESEARCH (2017)
Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression
Muming Yu et al.
MOLECULAR MEDICINE REPORTS (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
William C. Dougall et al.
IMMUNOLOGICAL REVIEWS (2017)
Co-expression of TIM-3 and CEACAMI promotes T cell exhaustion in colorectal cancer patients
Yang Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma
Liang Mao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Cutting Edge: Anti-TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice
Takuma Isshiki et al.
JOURNAL OF IMMUNOLOGY (2017)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
Hojabr Kakavand et al.
MODERN PATHOLOGY (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer.
Spencer Liang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes
Qianxia Zhang et al.
SCIENCE IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Identification of CD112R as a novel checkpoint for human T cells
Yuwen Zhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
Susan P. Foy et al.
PLOS ONE (2016)
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
Rachelle G. Veenstra et al.
BLOOD (2015)
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T-Cells, Which Dampen CD8+ T-cell Antitumor Reactivity
Marco Donia et al.
CANCER RESEARCH (2015)
Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
Chamutal Gur et al.
IMMUNITY (2015)
TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients
Joe-Marc Chauvin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
Nicole Joller et al.
IMMUNITY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Giuseppina Della Vittoria Scarpati et al.
ONCOTARGETS AND THERAPY (2014)
Structure and Cancer Immunotherapy of the B7 Family Member B7x
Hyungjun Jeon et al.
CELL REPORTS (2014)
CTLA-4 and autoimmunity: New insights into the dual regulator of tolerance
Jorge Romo-Tena et al.
AUTOIMMUNITY REVIEWS (2013)
A Disintegrin and Metalloprotease (ADAM) 10 and ADAM17 Are Major Sheddases of T Cell Immunoglobulin and Mucin Domain 3 (Tim-3)
Katja Moeller-Hackbarth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Nicola Gagliani et al.
NATURE MEDICINE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Deryk Loo et al.
CLINICAL CANCER RESEARCH (2012)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
Xin Gao et al.
PLOS ONE (2012)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hemon et al.
JOURNAL OF IMMUNOLOGY (2011)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
B7-H3 and Its Role in Antitumor Immunity
Martin Loos et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Valerie Dardalhon et al.
JOURNAL OF IMMUNOLOGY (2010)
T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
Rosemarie H. DeKruyff et al.
JOURNAL OF IMMUNOLOGY (2010)
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Hyun-Tak Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction
Judith Leitner et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Kent S. Boles et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Creg J. Workman et al.
JOURNAL OF IMMUNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses
Masaaki Hashiguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Metalloproteases regulate T-cell proliferation and effector function via LAG-3
Nianyu Li et al.
EMBO JOURNAL (2007)
B7-H3 and B7-H4 expression in non-small-cell lung cancer
Yuping Sun et al.
LUNG CANCER (2006)
Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction
D Pende et al.
BLOOD (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
M Kisielow et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity
GL Sica et al.
IMMUNITY (2003)
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance
CA Sabatos et al.
NATURE IMMUNOLOGY (2003)
Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2002)
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production
AI Chapoval et al.
NATURE IMMUNOLOGY (2001)
Share Paper
